In consultation: Guidance and quality standards
Showing 1 to 6 of 6
| Title | Consultation | Type | Consultation end date |
|---|---|---|---|
| Iptacopan for treating complement 3 glomerulopathy [ID6283] | Draft guidance | Technology appraisal guidance | |
| Talquetamab for treating relapsed or refractory multiple myeloma after 3 treatments [ID5082] | Draft guidance | Technology appraisal guidance | |
| Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004] | Draft guidance | Technology appraisal guidance | |
| Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223] | Draft guidance | Technology appraisal guidance | |
| Zuranolone for treating postnatal depression [ID6431] | Draft guidance | Technology appraisal guidance | |
| Sotatercept for treating pulmonary arterial hypertension [ID6163] | Draft guidance | Technology appraisal guidance |